Will apoA-I-based therapies step up to cure coronary artery disease?

References

• No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333(20), 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med,62(5), 707–714 (1977).
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med.357(13), 1301–1310 (2007).
   PubMed Web of Science ®Google Scholar
• Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab. Invest.60(3), 455–461 (1989).
   PubMed Web of Science ®Google Scholar
• Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature353, 265–267 (1991).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Cutri B, Worthley SG et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler. Thromb. Vasc. Biol.25(11), 2416–2421 (2005).
   PubMed Web of Science ®Google Scholar
• Rong JX, Li J, Reis ED et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation104, 2447–2452 (2001).
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr. Cardiol. Rep.9(6), 486–492 (2007).
   PubMedGoogle Scholar
• Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ. Res.95(8), 764–772 (2004).
   PubMed Web of Science ®Google Scholar
• Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA285(12), 1585–1591 (2001).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Tuzcu EM, Sipahi I et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA297(5), 499–508 (2007).
   PubMed Web of Science ®Google Scholar
• Cui Y, Watson DJ, Girman CJ et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am. J. Cardiol.104(6), 829–834 (2009).
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao X-Q, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med.345, 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation110(23), 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361(22), 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol.8(6), 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Bisoendial RJ, Hovingh GK, Levels JHM et al. restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation107(23), 2944–2948 (2003).
   PubMed Web of Science ®Google Scholar
• Spieker LE, Sudano I, Hurlimann D et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation105, 1399–1402 (2002).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA290(17), 2292–2300 (2003).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L’Allier PL et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA297(15), 1675–1682 (2007).
   PubMed Web of Science ®Google Scholar
• Waksman R, Torguson R, Kent KM et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol.55(24), 2727–2735 (2010).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357(21), 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med.356(13), 1304–1316 (2007).
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet370(9582), 153–160 (2007).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N. Engl. J. Med.356(16), 1620–1630 (2007).
   PubMed Web of Science ®Google Scholar
• Vergeer M, Stroes ES. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Am. J. Cardiol.104(10 Suppl.), E32–E38 (2009).
   PubMed Web of Science ®Google Scholar
• Sherman CB, Peterson SJ, Frishman WH. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis. Cardiol. Rev.18(3), 141–147 (2010).
   PubMed Web of Science ®Google Scholar
• Bailey D, Jahagirdar R, Gordon A et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol.55(23), 2580–2589 (2010).
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Gordon A, Johansson J et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J. Am. Coll. Cardiol.57(9), 1111–1119 (2011).
   PubMed Web of Science ®Google Scholar
• Khera AV, Cuchel M, de la Llera-Moya M et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med.364(2), 127–135 (2011).
   PubMed Web of Science ®Google Scholar